Is IART Still Attractive as Its Low Valuation Meets Execution Risks?
Integra LifeSciences Holdings Corp. (IART) trades at a significant valuation discount compared to its industry and market benchmarks, driven by recent margin gains and improved operating execution. However, the company faces challenges including modest revenue growth, elevated leverage, and unresolved regulatory remediation with the FDA. Despite these risks, Integra's operational improvements and cost savings offer support for its earnings outlook, making execution crucial for its investment appeal.
Integra LifeSciences /US Number of Employees 2026 | Employee Count & Headcount Data
Integra LifeSciences Holdings Corp. (IART) had approximately 4,344 employees worldwide as of March 2026, representing a 0.6% decline from 2023. The company is actively hiring, with 272 active job postings in 2026, though this is a significant decline from previous years. The workforce is concentrated in North America, and overall employee sentiment is reported as negative and declining.
Assenagon Asset Management S.A. Reduces Position in Integra LifeSciences Holdings Corporation $IART
Assenagon Asset Management S.A. significantly reduced its stake in Integra LifeSciences Holdings Corporation by 66.3% in the second quarter of 2026, selling over 276,000 shares. Despite this, other institutional investors like Rubric Capital Management LP and Paradigm Capital Management Inc. NY increased their holdings. The stock opened up 4.9% at $18.24 following a beat on quarterly EPS and revenue, with analysts maintaining a cautious "Reduce" average rating but an Argus upgrade to "Buy."
Paradigm Capital discloses 4.42% Integra LifeSciences (IART) stake with sole voting control
Paradigm Capital Management, Inc. has reported an amended stake in Integra LifeSciences Holdings Corp (IART), disclosing beneficial ownership of 3,439,098 shares, which represents 4.42% of the outstanding common stock. The New York S corporation maintains sole voting and dispositive power over all these shares. This filing characterizes their holding as ownership of 5 percent or less of the class, aligning with regulatory reporting thresholds.
Quantinno Capital Management LP Reduces Holdings in Integra LifeSciences Holdings Corporation $IART
Quantinno Capital Management LP significantly reduced its stake in Integra LifeSciences Holdings Corporation (NASDAQ:IART) by 45.4% in the first quarter of 2026, selling 382,663 shares. Despite this reduction, other institutional investors like Paradigm Capital, Sei Investments, and Walleye Capital increased their holdings, maintaining high institutional ownership at 84.78%. Integra LifeSciences exceeded Q1 2026 earnings expectations with $0.56 EPS and $418.76 million in revenue, but analysts maintain a cautious "Reduce" rating with an average price target of $18.86.
5 Must-Read Analyst Questions From Integra LifeSciences’s Q2 Earnings Call
Integra LifeSciences reported Q2 results with flat revenue due to reimbursement pressures and challenging year-over-year comparisons, though adjusted EPS outperformed expectations. Analysts focused on the company's full-year guidance, CEO's return, demand for Integra Skin, and the relaunch of SurgiMend. Upcoming quarters will see monitoring of SurgiMend's relaunch, cost savings, and supply chain stability.
Integra LifeSciences Holdings Corporation $IART Stock Position Trimmed by Dimensional Fund Advisors LP
Dimensional Fund Advisors LP reduced its stake in Integra LifeSciences Holdings Corporation (NASDAQ:IART) by 10.1% in the first quarter, although institutional investors still collectively own 84.78% of the company's stock. Integra LifeSciences recently reported Q2 EPS of $0.56, exceeding analyst estimates, and provided Q3 and full-year 2026 guidance. Analyst sentiment remains cautious, with a consensus "Reduce" rating and an average price target of $18.86.
integra lifesciences holdings corp Profit Warnings
This page provides information on Integra Lifesciences Holdings Corp's profit warnings and related financial news. It lists a specific profit warning for FY26 with a revised revenue range. The page also features a compilation of recent news articles concerning Integra LifeSciences, detailing earnings, leadership changes, and FDA clearances.
Integra LifeSciences (IART) 10K Form and Latest SEC Filings 2026
This article details Integra LifeSciences' (IART) SEC filings history, emphasizing that these documents are crucial for investors as a primary source of verified financial data. It highlights the company has submitted over 437 documents since 2017, with the most recent being a Form SCHEDULE 13G on July 31, 2026. The article also explains the importance and differences between common SEC filing types like 10-K, 10-Q, 8-K, and Form 4, providing a comprehensive overview for investors tracking IART.
Vanguard Portfolio Management (IART) discloses 3.9M-share position in Integra
Vanguard Portfolio Management has disclosed a beneficial ownership of 3,912,816 shares, representing 5.02% of Integra LifeSciences Holdings Corp (IART) common stock, as of June 30, 2026. This Schedule 13G filing indicates Vanguard has sole voting power over 169,723 shares and sole dispositive power over all 3,912,816 shares, with no shared voting or dispositive power. The filing also clarifies that no other single entity has an interest in more than 5% of these reported securities.
Zacks.com featured highlights include Bassett Furniture, Aveanna Healthcare and Integra LifeSciences
Zacks.com has identified Bassett Furniture Industries (BSET), Aveanna Healthcare Holdings (AVAH), and Integra LifeSciences Holdings (IART) as stocks with breakout potential ahead of August. The article emphasizes identifying stocks within defined trading ranges and highlights the importance of support and resistance levels to spot genuine breakout opportunities. These three companies are recommended based on their Zacks Rank and expected earnings growth rates.
Integra Lifesciences Holdings Corp (IART) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis for Integra Lifesciences Holdings Corp (IART), highlighting its current valuation score of 8.05, which ranks 83rd in the Healthcare Equipment & Supplies industry. It details the company's current P/E ratio at -2.58, noting significant deviations from recent highs and lows. The analysis also indicates that relevant data for P/B, P/S, and P/CF ratios have not yet been disclosed by the company.
IART|Integra Lifesciences Holdings Corp|Price:17.842|Chg%:+1.192
This article provides a detailed profile of Integra LifeSciences Holdings Corporation (IART), a global medical technology company. It outlines the company's two main segments, Codman Specialty Surgical (CSS) and Tissue Technologies (TT), and their respective product portfolios. The report also includes company information, key executive details with their shareholdings, and FAQs regarding top shareholders, institutional holdings, and primary revenue sources.
Zacks.com featured highlights include Bassett Furniture, Aveanna Healthcare and Integra LifeSciences
This article identifies Bassett Furniture Industries (BSET), Aveanna Healthcare Holdings (AVAH), and Integra LifeSciences Holdings (IART) as potential breakout stocks for August. It outlines a strategy for spotting such opportunities by analyzing support and resistance levels. The article emphasizes that while correctly identifying these stocks can lead to significant returns, investors should be aware of the risks involved in timing breakout candidates.
Integra Lifesciences Q3 Results: Sales guidance beats estimates
Integra Lifesciences projects Q3 adjusted EPS between $0.53-$0.61 and sales of $410-$425 million, with the sales guidance exceeding analyst estimates. While profit expectations align with consensus, the higher sales forecast indicates potential revenue upside. This guidance highlights the company's confidence in maintaining demand and managing costs effectively amidst varying market dynamics.
Integra Lifesciences Latest Results: Sales guidance lowered to $1.654B-$1.695B
Integra Lifesciences has lowered its sales guidance for FY2026 to a range of $1.654 billion to $1.695 billion, which is below the analyst consensus estimate of $1.676 billion. Despite this downward revision in revenue, the company affirmed its adjusted earnings per share (EPS) guidance at $2.40 to $2.50, matching analyst estimates. This indicates a focus on maintaining profitability through cost efficiencies or margin expansion even with anticipated weaker top-line growth.
Integra: Q2 Earnings Snapshot
This article provides a second-quarter earnings snapshot for Integra.
Integra LifeSciences Reports Second Quarter 2026 Results, Updates Full-Year Revenue Guidance and Reaffirms EPS Outlook
Integra LifeSciences announced its Q2 2026 financial results, reporting revenues of $418.8 million and a significant improvement in GAAP net income from a loss to $4.5 million. The company updated its full-year revenue guidance due to foreign exchange impacts but reaffirmed its organic growth and adjusted EPS outlook. Integra also highlighted operational progress, including the start of production at its Braintree facility for the SurgiMend relaunch.
Integra starts production for planned fourth-quarter SurgiMend relaunch
Integra LifeSciences (Nasdaq: IART) reported Q2 2026 revenue of $418.8 million, a 0.8% increase year-over-year, with GAAP EPS at $0.06 and adjusted EPS at $0.56. The company reaffirmed its full-year 2026 organic revenue growth and adjusted EPS guidance, while slightly lowering reported revenue guidance due to foreign exchange impacts. Crucially, Integra initiated production at its Braintree facility, staying on track for a planned fourth-quarter relaunch of its SurgiMend product.
Integra LifeSciences earnings up next: Can turnaround hold?
Integra LifeSciences is set to report second-quarter earnings, with investors looking for sustained operational recovery following manufacturing issues. Analysts project $0.48 EPS and $417.6 million in revenue, but maintain a neutral rating due to past guidance cuts and questions about consistent results. The company's ability to maintain or raise guidance and expand its gross margin will be key indicators of whether its recent performance signals a true turnaround.
Integra Lifesciences Holdings Corp (IART) Dividends & Stock Splits: Historical Payouts and Event Timeline
The article provides an overview of Integra Lifesciences Holdings Corp's (IART) dividend history and stock splits. It states that the company has distributed a total of $0.00 in dividends over the past five years, indicating no recent dividend payouts. Key information like market cap, P/E ratio, and current stock price is also displayed.
Integra Lifesciences Holdings Corp
This article provides a detailed revenue breakdown for Integra Lifesciences Holdings Corp (IART) by business segments and geographical regions. It shows Neurosurgery as the largest revenue contributor among business segments, and the United States as the dominant region for its revenue. The financial data is updated as of April 6, covering fiscal years up to 2025.
IART|Integra Lifesciences Holdings Corp|Price:19.530|Chg%:-0.260
This article provides a comprehensive stock analysis of Integra Lifesciences Holdings Corp (IART) based on TradingKey's stock score system. It highlights the company's stable fundamentals, high growth potential, and fair valuation within the Healthcare Equipment & Supplies industry. The analysis also notes high institutional ownership, a "Hold" analyst rating, and an expectation for the stock price to trend upward in the medium term, despite recent average market performance.
IART|Integra Lifesciences Holdings Corp|Price:19.790|Chg%:+1.230
This article provides a detailed financial overview of Integra Lifesciences Holdings Corp (IART), including its stock price, market capitalization, and upcoming earnings date. It presents a comprehensive data dashboard with quarterly and annual financial statements such as income statement, balance sheet, and cash flow statement. Key financial indicators like EPS, revenue, net profit, and various margins are displayed, alongside answers to frequently asked questions regarding the company's financial performance.
TradingKey
This article provides a detailed quarterly and annual balance sheet analysis for Integra Lifesciences Holdings Corp (IART) from FY2012Q1 to FY2026Q1, highlighting various asset, liability, and equity metrics. It allows users to evaluate the company's financial health, fundamentals, and key ratios. The report includes year-over-year percentage changes and absolute values for items like cash, receivables, inventory, debt, and shareholder equity.
Integra Lifesciences Holdings Corp (IART) Cash Flow Statement
This article presents the quarterly and annual cash flow statements for Integra Lifesciences Holdings Corp (IART), allowing users to assess the company's financial health. It includes detailed breakdowns of operating, investing, and financing cash flows, along with frequently asked questions defining these terms and providing IART's recent figures.
Integra LifeSciences Holdings Corporation (IART) Stock Price, News, Quote & History
This article provides a comprehensive overview of Integra LifeSciences Holdings Corporation (IART), including its current stock price, financial statistics, and company profile. It details the company's performance, product offerings in medical devices, and recent analyst ratings. The information aims to give investors a snapshot of IART's financial health and market position.
Integra Lifesciences Holdings Corp (IART) Financial Health: Profitability & Balance Sheet Analysis
This article analyzes the financial health of Integra Lifesciences Holdings Corp (IART), noting its weak financial status but high operating efficiency. The company's financial score is 6.96, ranking 121 out of 200 in its industry. Integra Lifesciences recently reported a 2.42% year-over-year revenue increase and an 81.75% increase in net profit.
Kaskela Law Firm Announces Investigation of Integra LifeSciences
Kaskela Law Firm has launched an investigation into Integra LifeSciences Holdings Corp. (NASDAQ: IART) following the filing of a securities fraud complaint. The complaint alleges that Integra made false and misleading statements regarding systemic cGMP violations and product quality issues from March 2019 to May 2023, leading to a significant stock price drop after these deficiencies were disclosed. The firm is encouraging long-term shareholders with losses who purchased shares before April 26, 2023, to contact them to discuss their legal rights.
Integra Lifesciences Holdings Corp|Price:19.790|Chg%:+1.230
Integra Lifesciences Holdings Corp (IART) saw a price increase of 6.63% to $19.790, with its fundamentals noted as stable and growth potential high, despite technical indicators not fully supporting the current trend. The stock is currently trading sideways, suitable for range-bound swing trading, and analysts rate it as Hold with a target price of $18.833. The company is a global medical technology firm operating in two main segments: Codman Specialty Surgical and Tissue Technologies.
Integra LifeSciences to announce Q2 2026 results on July 29
Integra LifeSciences Holdings Corporation announced it will release its second-quarter 2026 financial results on July 29, 2026, before the market opens. Following the release, the management team will host a conference call at 8:30 a.m. ET to discuss the results and outlook, with a live webcast available on the company's investor website. This announcement comes after BMO Capital initiated coverage on Integra Lifesciences with a Market Perform rating and a $19 price target.
Integra LifeSciences to Release Results Before Market Open July 29
Integra LifeSciences (NASDAQ: IART) announced that it will release its second-quarter 2026 financial results on Wednesday, July 29, 2026, before the market opens. Management will host an earnings conference call at 8:30 a.m. ET, which will be accessible via live webcast and replay on the company's investor relations website. Following this announcement, the stock saw a positive market reaction, gaining 5.38% and adding approximately $79 million to its valuation.
Integra LifeSciences to Host Second Quarter 2026 Financial Results Conference Call on July 29, 2026
Integra LifeSciences Holdings Corporation will release its second quarter 2026 financial results on Wednesday, July 29, 2026, before the market opens. Following the release, the management team will host a conference call at 8:30 a.m. ET, with a live webcast available on the company's investor relations website. A webcast replay will also be accessible on the website after the call.
Integra LifeSciences stock hits 52-week high at 18.93 USD
Integra LifeSciences Holdings (IART) stock has reached a new 52-week high of $18.93, representing a 54.13% increase over the past year and a 113% surge from its 52-week low. This milestone follows the company's strong first-quarter 2026 financial results, which exceeded analyst expectations, and positive analyst coverage, including an upgrade to Buy by Argus. InvestingPro analysis indicates the stock remains undervalued despite its recent gains.
ETFs Investing in Integra LifeSciences Holdings Corporation Stocks
This article lists various ETFs that invest in Integra LifeSciences Holdings Corporation (IL3) stocks, sorted by market value. It provides key details for each ETF, such as market value, weight of IL3 in the fund, issuer, management style, focus, expense ratio, AUM, price change, and 3-year NAV total return. The ETFs predominantly focus on small-cap and healthcare sectors, making investing in IL3 more accessible while offering diversification.
BMO initiates Integra LifeSciences stock at Market Perform
BMO Capital initiated coverage on Integra LifeSciences Holdings Corp. (NASDAQ:IART) with a Market Perform rating and a $19.00 price target. The firm highlighted the return of CEO Essig, strong Q1 2026 earnings, and record Integra Skin production as positive signs. Despite a 46% year-to-date rise in shares, BMO Capital notes that key catalysts are still ahead for the company, which has seen three years of guidance cuts.
BMO initiates Integra LifeSciences stock at Market Perform By Investing.com
BMO Capital has initiated coverage on Integra LifeSciences Holdings Corp. (NASDAQ:IART) with a Market Perform rating and a price target of $19.00. The firm highlighted the operational continuity provided by CEO Essig's return and early signs of recovery, including a Q1 2026 earnings beat and record Integra Skin production. Despite a 46% year-to-date rise in shares, BMO notes that the positive outlook might already be priced in, while acknowledging key catalysts still lie ahead.
BMO initiates Integra LifeSciences stock at Market Perform By Investing.com
BMO Capital has initiated coverage on Integra LifeSciences Holdings Corp. (NASDAQ:IART) with a Market Perform rating and a price target of $19.00. The firm notes that the return of CEO Essig provides operational continuity and early signs of recovery, including a Q1 2026 earnings beat and record Integra Skin production. Despite the positive outlook and a 46% year-to-date gain, BMO Capital suggests the stock's current valuation already reflects much of this optimism, with key catalysts still ahead.
Integra Lifesciences (NASDAQ: IART) SVP uses 937 shares for tax withholding
Jeffrey Mosebrook, SVP and Principal Accounting Officer of Integra Lifesciences (NASDAQ: IART), reported a tax-related share disposition where 937 common shares were delivered at $17.89 each to satisfy tax obligations. Following this transaction, Mr. Mosebrook directly holds 34,516 shares of the company's common stock. This "F" coded transaction indicates shares were used for tax liability payment rather than an open-market sale.
Integra LifeSciences (IART) EVP awarded 11,180 RSUs in new equity grant
Integra LifeSciences Holdings Corp's EVP, Robert T. Davis Jr., has been granted 11,180 restricted stock units (RSUs) as part of his equity compensation. These RSUs, which represent a contingent right to receive one share of common stock each, will vest in full on the second anniversary of the grant date, provided Davis remains with the company. Following this award, his direct holdings of RSUs total 54,530.
Integra LifeSciences (IART) grants EVP 5,590 RSUs vesting over 3 years
Integra LifeSciences (IART) has granted Harvinder Singh, EVP & President, SS, 5,590 restricted stock units (RSUs) under its 2003 Equity Incentive Plan. These RSUs will vest in three equal annual installments over three years, contingent on his continued service. Following this grant, Mr. Singh's direct holdings of RSUs total 68,883.
Integra Lifesciences Holdings Corp (IART) Stock Forecast, Price Targets and Analysts Predictions
This article provides a stock forecast, price targets, and analyst predictions for Integra Lifesciences Holdings Corp (IART). It details the current market capitalization, enterprise value, PE Ratio, and PB Ratio, along with its GuruFocus score. The content primarily serves as an overview for investors interested in IART's financial data and analyst coverage.
Integra LifeSciences Appoints Topaz Kirlew Chief Regulatory Officer
Integra LifeSciences Holdings Corporation has appointed Topaz Kirlew as its corporate vice president and chief regulatory officer. Kirlew will be responsible for leading the company's global regulatory affairs organization, overseeing strategy, compliance, submissions, and transformation initiatives. She has extensive experience in the healthcare and medical technology industries, having served as interim regulatory leader for Integra and held roles at various other organizations.
Integra LifeSciences Names Topaz Kirlew Chief Regulatory Officer
Integra LifeSciences Holdings Corp. has appointed Topaz Kirlew as corporate vice president and chief regulatory officer. Kirlew will oversee the company's global regulatory strategy, submissions, compliance, and transformation initiatives, bringing over 35 years of experience in healthcare and medical technology regulatory affairs. Her appointment aims to strengthen Integra's compliance and quality systems during a period of increasingly complex global regulatory requirements.
Integra LifeSciences taps interim regulatory chief for global role
Integra LifeSciences (Nasdaq: IART) has appointed Topaz Kirlew as corporate vice president and chief regulatory officer, where she will lead global regulatory affairs and strategy. Kirlew previously served as interim regulatory leader, bringing over 35 years of experience in healthcare and medical technology across various regulatory, quality, operations, clinical, and laboratory roles. Her appointment aims to strengthen the company’s regulatory capabilities and reinforce compliance.
Integra LifeSciences Appoints Topaz Kirlew Chief Regulatory Officer
Integra LifeSciences has appointed Topaz Kirlew, DBA, MBA, as its corporate vice president and chief regulatory officer. Kirlew will be responsible for leading the company's global regulatory affairs organization, overseeing strategy, compliance, submissions, and transformation initiatives. She has extensive experience in the healthcare and medical technology industries, having served as interim regulatory leader for Integra and held roles at various other organizations.
Integra LifeSciences Appoints Topaz Kirlew Chief Regulatory Officer
Integra LifeSciences has appointed Topaz Kirlew as its corporate vice president and chief regulatory officer. Kirlew will lead the company's global regulatory affairs organization, overseeing strategy, compliance, submissions, and transformation initiatives worldwide. She brings over 35 years of experience in healthcare and medical technology and has been instrumental in building the company's regulatory capabilities since joining in 2021.
Integra LifeSciences Holdings (IART) Could Be 31% Undervalued Following Leadership Changes
Integra LifeSciences Holdings (IART) has restructured its commercial leadership, appointing new executives to enhance execution and customer focus. Despite a weak five-year shareholder return, the company shows strong recent momentum, trading at $18.74 with a fair value estimated at $27.00, suggesting it is 30.6% undervalued. This valuation is based on expected operational improvements, margin recovery, and long-term earnings growth, though regulatory and pricing risks remain.
Integra LifeSciences Holdings stock hits 52-week high at $18.30
Integra LifeSciences Holdings (IART) stock has reached a new 52-week high of $18.30, more than doubling its 52-week low. This surge is attributed to robust performance, including impressive Q1 2026 financial results that surpassed analyst expectations and an upgrade to a Buy rating by Argus. InvestingPro analysis suggests the stock remains undervalued despite its recent gains, indicating strong potential for future growth.
Zacks.com featured highlights TPG Mortgage Investment Trust, Silvercorp and Integra LifeSciences
The article highlights TPG Mortgage Investment Trust (MITT), Silvercorp Metals Inc. (SVM), and Integra LifeSciences Holdings Corp. (IART) as strong investment opportunities based on recent broker rating upgrades. These upgrades signal potential upside driven by improved analyst outlooks, although investors are advised to consider these recommendations alongside other fundamental and valuation factors. The companies show strong projected earnings growth for their respective fiscal years.
